Table 3

Echocardiographic short axis data

Baseline3 monthsp Value6 monthsp Value12 monthsp ValueANOVA
Placebo/metoprolol (n)12/2910/2110/2811/27
Interventricular septum wall thickening (mm)P−0.1 (1.2)0.3 (0.77)0.3 (0.97)0.3 (1.3)0.87
M0.5 (1.2)0.7 (1.5)0.7 (1.8)0.6 (1.1)0.35
Posterior wall thickening (mm)P4.1 (2.2)3.4 (2.1)4.1 (2.0)3.9 (1.5)0.83
M3.3 (2.1)4.1 (2.1)< 0.054.0 (2.4)< 0.054.7 (2.0)< 0.050.006
Fractional shortening (%)P13 (2.1)13 (2.9)14 (4.7)14 (4.9)0.71
M12 (4.6)16 (5.7)< 0.0516 (6.4)< 0.0517 (5.8)< 0.05< 0.001
Maximum left ventricular ejection, dD/dt (cm/s)P4.1 (1.0)4.4 (0.83)4.6 (1.1)4.8 (0.82)0.32
M4.5 (1.2)5.0 (1.6)5.1 (1.7)5.3 (1.4)0.11
Maximum left ventricular filling, dD/dt (cm/s)P8.3 (2.6)8.8 (2.2)8.3 (2.4)8.9 (2.4)0.95
M8.3 (2.6)9.1 (4.0)8.2 (2.8)8.9 (3.0)0.74
Maximum interventricular septal wall thickening, dD/dt (cm/s)P1.6 (0.46)1.7 (0.83)2.0 (0.60)2.0 (0.66)0.09
M2.1 (1.1)2.2 (1.4)2.3 (1.1)2.2 (0.94)1.00
Maximum interventricular septal wall thinning, dD/dt (cm/s)P1.3 (0.91)1.6 (0.90)NS1.7 (1.1)NS2.2 (1.0)< 0.050.02
M1.7 (1.2)2.0 (1.8)2.0 (1.3)2.3 (1.4)1.00
Maximum posterior wall thickening, dD/dt (cm/s)P3.1 (0.87)3.2 (1.1)3.2 (0.89)3.2 (0.91)0.95
M3.0 (1.1)3.5 (1.1)3.1 (1.1)3.5 (1.0)0.52
Maximum posterior wall thinning, dD/dt (cm/s)P5.9 (1.7)5.3 (2.4)5.1 (1.6)5.6 (1.6)0.44
M5.3 (1.9)5.9 (2.8)5.0 (2.0)5.6 (1.8)0.74
  • ANOVA column denotes significance of testing a repeated measurements analysis of variance within respective group, followed by comparison with baseline value using Dunnett's test; –, no test performed.

  • M, metoprolol; P, placebo.